Prenatal blockade of vasoactive intestinal peptide alters cell death and synaptic equipment in the murine neocortex.
Vasoactive intestinal peptide (VIP) is a potent growth factor that stimulates murine neocortical astrocyte genesis during the period of ontogenesis corresponding to premature delivery in humans. In rodents, part of the VIP supplied to the fetal brain is maternal VIP that crosses the placenta. If these data also apply to human brain development, premature newborns may be partly VIP-deficient because of loss of the maternal supply, and this may adversely affect their brain development. The goal of the present study was to determine the effects of VIP blockade during mouse neocortical astrocyte genesis on neuritic survival and maturation. VIP blockade by a specific VIP antagonist on embryonic d 17 and 18 induced transient, postnatal depletion of astrocytes in the upper neocortical layers. Combined use of in situ DNA fragmentation analysis (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method, a marker of cell death); immunohistochemical detection of synaptophysin, microtubule-associated proteins, and neurofilaments; and quantification of mRNA for synaptophysin and N-methyl-D-aspartate R1 receptor subunit revealed that early VIP blockade significantly altered programmed neuritic death and impaired neuritic differentiation. VIP inhibition induced 1) exaggerated postnatal terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling of cortical neurons, 2) long-term overexpression of synaptophysin and N-methyl-D-aspartate R1 receptor subunit, and 3) long-term overexpression of microtubule-associated protein-5 and neurofilament 160 kD. Although the functional consequences of this deviant pattern of murine neocortical development remain to be determined, these data open up new avenues for investigating some of the cognitive deficits observed in human premature infants.
Zupan
V
V
INSERM E 9935, Hôpital Robert-Debré, Paris, France.
Nehlig
A
A
Evrard
P
P
Gressens
P
P
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001483:Base Sequence; D017931:DNA Primers; D005333:Fetus / Q000166:cytology / Q000187:drug effects*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D019579:Neocortex / Q000166:cytology / Q000187:drug effects* / Q000196:embryology; D018919:Neovascularization, Physiologic; D013569:Synapses; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors*
D017931:DNA Primers; D014660:Vasoactive Intestinal Peptide; D005947:Glucose